- Previous Close
2.6700 - Open
2.6600 - Bid 2.7100 x 200
- Ask 2.7600 x 100
- Day's Range
2.6100 - 2.7700 - 52 Week Range
2.3350 - 6.0550 - Volume
930,939 - Avg. Volume
2,186,553 - Market Cap (intraday)
812.257M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date Feb 18, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.29
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
www.abcellera.comRecent News: ABCL
View MorePerformance Overview: ABCL
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABCL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABCL
View MoreValuation Measures
Market Cap
788.63M
Enterprise Value
216.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.74
Price/Book (mrq)
0.73
Enterprise Value/Revenue
6.58
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.26%
Return on Equity (ttm)
-15.55%
Revenue (ttm)
32.96M
Net Income Avi to Common (ttm)
-175.8M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
643.14M
Total Debt/Equity (mrq)
6.62%
Levered Free Cash Flow (ttm)
-105.58M